IsoTherapeutics Group, LLC

Radiopharmaceutical R&D and Consulting

Home

Welcome to IsoTherapeutics Group!

Company Profile

Our purpose is to develop novel diagnostic and therapeutic agents directed at debilitating diseases. We develop our own technologies as well as partner with other companies to help them develop pharmaceuticals. Of special interest are therapeutic radiopharmaceuticals for oncology.

News at IsoTherapeutics

Kenneth McMillan Memorial Scholarship

The Kenneth McMillan Memorial Scholarship is being initiated to honor the memory of our late long-term friend and colleague. This will be an annual scholarship awarded to a deserving high school senior from the Brazosport Independent School District.

Success Stories

Open Communication and organized learning solved a customer's problem

Problem: While working in close concert with a customer for developing a radiolabeled protein for diagnosing vulnerable plaque, a major problem arose in the midst of the project when the customer lost the ability to process their isotope. Without an alternate source of supply of isotope there was a strong probability that the product development and subsequent path to clinical trial may have to be delayed.

Expertise is Our Strength

ITG has set up a series of competencies for the purpose of aiding our customers/collaborators in the development of pharmaceuticals. The scientific staff at ITG has extensive experience in the development of radiopharmaceuticals, particularly bone-seeking radiopharmaceuticals. Additionally, we have experience designing antibody conjugates for radioimmunotherapy.

Our model is to house the necessary capabilities under one roof to shorten the development time for drug candidates. Capabilities include synthetic organic and chelation chemistry, with particular expertise in bifunctional chelants for radiolabeling proteins. Additional capabilities include radioanalytical and radiochemistry, with expertise in diagnostic and therapeutic isotopes. Small animal testing capabilities include the ability to perform biodistribution and pharmacokinetic studies on normal and tumor xenograft models using radiolabeled compounds.

Last Update 23 June 2009